1 BTC
=
- USD
IMAC Holdings, Inc. Common Stock
As of May 29, 2026 at 24:07 UTC
Chart
About IMAC Holdings, Inc. Common Stock
IMAC Holdings Inc is a provider and manager of value-based, conservative medical care combining life science advancements with traditional medical care for movement-restricting diseases and conditions in IMAC Regeneration Centers and BackSpace clinics. Its Innovative Medical Advancements and Care (IMAC) Regeneration Centers combine medical and physical procedures to improve patient experiences and outcomes and reduce healthcare costs as compared to other available treatment options.
Market Statistics
Trading Metrics
How to Buy BACK
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BACK
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesAllarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.
IMAC Holdings, Inc. received a notification from Nasdaq regarding its failure to timely file its quarterly report. The company is working to file the report and regain compliance with Nasdaq's listing rules, but there is no assurance it will be able to do so within the required timeframe.
IMAC Holdings, Inc. received a notification from Nasdaq regarding its failure to timely file its quarterly report. The company is working to file the report and regain compliance with Nasdaq's listing rules, but there is no assurance it will be able to do so within the required timeframe.
IMAC Holdings, Inc. announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, strengthening its expertise in proteomics research and precision oncology.
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin